Introduction
Alpha-synuclein (aS) is a small, acidic synaptic protein composed of 140 amino acid residues, normally soluble, which is abundantly localized in the neuronal synaptic terminals of the brain [1] . Under certain physiological conditions, aS participates in the synaptic function. An increased intracytoplasmic aggregation of aS is the major component of the pathologic inclusions in the neurodegenerative diseases, including Parkinson disease [2, 3] , dementia with Lewy bodies (LB) (DLB) [2] , multiple systems atrophy (MSA) [2] , LB variant of Alzheimer disease (LBVAD), and alcoholism [4] . The aS-immunostained perikaryal granules present in the neurons of the substantia nigra and medulla, as well as the glial cytoplasmic inclusions are within the pathologic spectrum of aS actions and the phosphorylated aS lesions as previous described study [5] . In previously mentioned diseases this protein is considered as a biochemical prognostic marker [3, 6] .
aS is abundant in the presynaptic nerve terminals within the supragranule region of the dentate after the pilocarpine-induced repetitive seizure occurrence [7, 8] . It is mainly localized in the neocortex, olfactory bulb, striatum, and thalamus hippocampus, substantia nigra, thalamus, and cerebellum [9, 10] . It is predominantly a neuronal protein, but can also be found in the neuroglial cells. It affects the synaptic transmission via the regulation of neurotransmitter release and vesicle recycling [1, 11] . Mesial temporal lobe epilepsy, the most common form of epilepsy, is characterized by aS abnormal deposits, including neuronal cell loss and reactive gliosis in the hippocampus [7, 8] .
Epilepsy is a chronic disease of the central nervous system. The diagnosis of epilepsy is based mainly on the patient's medical history and the results from the electroencephalogram, but there is a lack of an objective biomarker. Approximately one-third of the patients are refractory to AEDs (antiepileptic drugs), and the disease in these cases has been defined as intractable epilepsy (IE) [12, 13] . For many years no reliable methods have existed to distinguish non-intractable epilepsy (NIE) from IE [12] . Therefore, a new clinical diagnostic biomarker would be of considerable practical importance to the clinical identification of the reactivity of patients to antiepileptic medications and the drug-resistant epilepsy [13, 14] .
Serum protein concentrations and CSF biomarkers have the advantage of being safe, easy, and inexpensive to obtain [3, 15] . In our study, we determined for the first time the concentrations of aS in the serum and CSF of epileptic patients and examined the changes of aS after the epileptic attack through ELISA measurements.
Methods and materials

Subjects
Patients were recruited from the Epilepsy Clinic, the Department of Neurology of the First Affiliated Hospital of Chongqing Medical University. All patients went through a comprehensive clinical examination, including an assessment of their medical history, neurological and psychiatric examinations, and an electroencephalogram performed by two professors. The cranial magnetic resonance imaging scans found no lesions in the central nervous system. Epilepsy was diagnosed as idiopathic and classified according to the criteria, proposed by the International League Against Epilepsy in 2001. The demographic data and final diagnoses are presented in Table 1 . Samples from 67 epileptic patients (33 men and 34 women) were collected by lumbar puncture. The age ranged from 17 to 68 years. The epilepsy group was divided into three subgroups, according to the criterion applied in a previous study [16] . 13 patients of the first one had been diagnosed with epilepsy for the first time (newly diagnosed epilepsy, NE), 14 patients were seizure-free for 3 months (NIE), and 40 had at least a 2-year history of seizure recurrence and IE.
Control samples were obtained from 22 individuals (age range from 15 to 70) with neurosis. Physical and laboratory examination, electrophysiologic study, brain MRI were showed the normal results for all controls. The lumbar was performed in order to exclude the central nervous disorders. Relevant clinical characteristics are summarized in Table 1 . This study was approved by the human research committee of Chongqing Medical University, and written informed consents were obtained from all participants before the study.
Sample collection and storage
2 ml of CSF and 5 ml of venous blood samples were collected from the subject after assigning the agreement. The blood samples were centrifuged at 3000 Â g for 5 min in order to collect the serum and then stored at À80 8C. CSF samples were centrifuged at 2000 Â g for 5 min and stored frozen at À80 8C until further analysis as previously described in detail [17] . 
aS measurement
The concentrations of serum-aS were measured by a commercial ELISA kit (Invitrogen, catalog #KHB0061). Operation steps were performed according to the manufacturer's protocol. Dilution of the serum and CSF was 1:10 and 1:1, respectively. Optical densities were determined with a Multiskan Spectrum Microplate Spectraphotometer microplate reader set to 450 nm (Thermo Fisher Scientific, USA) as previous [16] . A standard curve was constructed by plotting absorbance values versus aS concentrations of calibrators.
Statistical analysis
Statistical analysis was performed by SPSS Statistics 19.0. Descriptive data were computed using means AE standard deviation (S.D.). Differences between the epilepsy group and control group were assessed by the independent sample t-test, and one way analysis of variance (ANOVA) was used to compare all subgroups. Statistical significance was defined as p < 0.05.
Results
In the studied epilepsy group (67 patients), 50.7% of the subjects were women, and the average patient age was 39.84 years. The individual clinical and demographic data of the epilepsy patients are summarized in Table 1 . A part of the patients (19.4%) suffered from their first epilepsy occurrence and were defined as the NE subgroup; 59.7% of the patients had a longer than 2-year history of seizures, had been taking at least three types of AEDs regularly, and their seizures were not controlled: they were defined as the IE subgroup; 20.8% of the patients were defined as the NIE subgroup. There were 38 secondarily generalized tonic-clonic seizures (sGTCS), 18 generalized tonic-clonic seizures (GTCS), 35 complex partial seizures (CPS), and 11 simple partial seizures (SPS). Table 2 represents the clinical character of these cases. Fig. 1 shows the concentration of aS in the serum (Fig. 1A) and CSF (Fig. 1B) and in the epilepsy and the control groups. The concentrations of the serum aS in the epilepsy and control groups were 52.93 AE 22.11 ng/ml and 22.233 AE 12.68 ng/ml, respectively, and the difference was statistically significant. The level of aS in the CSF in the epileptic patients was considerably higher than that of the control group: 11.12 AE 4.18 ng/ml (epilepsy) versus 4.76 AE 2.37 ng/ ml.
As seen in Fig. 2 , the differences in the levels of aS in the CSF and serum in the different therapeutic reaction subgroups were statistically significant (p < 0.05). The concentrations of aS in the serum and CSF obtained from the IE subgroup were significantly higher than those in the NIE, NE, and control subgroups, whereas there was no difference in NIE, NE, and the control (p > 0.05).
Discussion
The results of our study reveal the high value of establishing the concentration of aS in CSF and serum as a candidate marker for the diagnosis of patients with epilepsy, especially for its drug-resistant form. The novel findings of this investigation can be summarized as follows: First, the concentration of the total aS in the CSF and serum should be assessed in the patients with IE. Second, the content of aS was increased in the CSF and serum from patients after IE, compared to the control, NE, and NIE. Third, there was no difference between the concentrations of aS in the serum and CSF in the patients with NE and NIE. Taken together, these results demonstrated that aS was associated with IE, but was not related to NIE and NE.
As already mentioned, aS is abundant in the presynaptic nerve terminals [1] and is suggested to play a role in the synaptic transmission via the regulation of neurotransmitter release and vesicle recycling [1, 11] , in the mitochondrial and synaptic dysfunction and neuronal apoptosis [1] , and in Ca 2+ homeostasis [18] . The intracytoplasmic aggregation of aS in patients can serve as a candidate marker for the diagnosis of Parkinson's disease, multiple system atrophy, dementia, and other neurodegenerative disorders [3] . The aggregated aS is believed to be involved in the pathogenesis of a previous disease. However, the underlying mechanisms are still unclear. Previous studies found that the elevated aS expression is associated with epileptogenesis [7, 8] . In the pilocarpine-induced status epilepticus (SE) models, the Western blot analysis of dentate lysates revealed that SE triggered a 12.8% increase in the aS expression. The immunohistochemical analysis detected an upregulation of aS within the supragranule region of the dentate gyrus [8] . Identical results were obtained in the hippocampus of patients with mesial temporal lobe epilepsy [7] .
The aS concentrations in CSF are exceedingly low in both the control and disease populations, making the assay development challenging [3] . The measured quantity of aS is nearly same in NE and NIE, nevertheless, found to be high in IE. This clearly emphasize that the increment in the amount of aS might be related with convulsive seizures activity. ELISA is more sensitive to the detection of the presence of proteins than the two-dimensional gel electrophoresis. Serum biomarkers have the advantage of being safe, easy, and inexpensive to obtain [3] . Therefore, in our study, we tested the expression of aS in the serum and CSF from epilepsy patients and found that it was increased in the intractable epilepsy patients. The mechanism leading to the elevated concentrations of aS in the CSF and serum was unclear. To our knowledge, the possible explanation of the rise of aS level was that the protein was able to pass the blood brain barrier (BBB) after seizures.
However, there are some limits in our study. First, aS exists in a number of different forms, including total and oligomeric aS, and its phosphorylated forms (Ser129, Ser87), while this study was designed for the detection of the total aS. There were also difficulties in obtaining the commercial ELISA agent. Nevertheless, our data showed a pathway for the correction of the drug-refractory, drugeffective, and newly diagnosed epilepsy. The conduction of future examinations is important to test the level of the oligomeric aS and the phosphorylation status of aS in epilepsy patients. Moreover, since previous studies had investigated the expression of this protein in animals and patients with epilepsy, we did not research its further activity mechanisms. Third, we did not test this protein by the use of a large number of samples because it is difficult to obtain CSF samples with recurrent epilepsy.
Conclusion
In conclusion, we revealed that the levels of aS in the serum and CSF were increased in the IE patients. aS could be a candidate biological marker in epilepsy and IE. However, these findings require further confirmation, and a larger number of epileptic patients with regular follow-up would enable us to understand better the potential role of aS in epilepsy.
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